Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1
- PMID: 14722894
- DOI: 10.1086/380802
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1
Abstract
Background: We wished to determine the safety and anti-human immunodeficiency virus (HIV) type 1 activity of single doses of TNX-355, a humanized IgG4 anti-CD4 monoclonal antibody with potent activity against HIV-1 in vitro, in HIV-infected subjects.
Methods: Sequential cohorts of 6 HIV-1-infected subjects each received infusions of TNX-355. Data included plasma HIV-1 RNA level, CD4+ T cell count, TNX-355 coating of CD4+ T cells, and serum TNX-355 levels.
Results: Dose-related reductions in plasma HIV-1 RNA loads correlated with complete CD4+ T cell coating by TNX-355. Peak median decreases in plasma HIV-1 RNA loads were 0.56, 1.33, and 1.11 log10 copies/mL and occurred on days 4-7, 14, and 21 for the 3.0, 10, and 25 mg/kg doses, respectively. Dose-dependent increases in CD4+ T cell count occurred within 24 h of dosing.
Conclusions: Single doses of TNX-355 reduced plasma HIV-1 RNA loads and increased CD4+ T cell counts in HIV-infected subjects. The further assessment of therapeutic potential awaits data from longer-duration trials.
Similar articles
-
Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.Antimicrob Agents Chemother. 2009 Feb;53(2):450-7. doi: 10.1128/AAC.00942-08. Epub 2008 Nov 17. Antimicrob Agents Chemother. 2009. PMID: 19015347 Free PMC article. Clinical Trial.
-
HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).AIDS. 1998 Mar 5;12(4):F1-8. AIDS. 1998. PMID: 9520161 Clinical Trial.
-
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.N Engl J Med. 2018 Aug 16;379(7):645-654. doi: 10.1056/NEJMoa1711460. N Engl J Med. 2018. PMID: 30110589 Clinical Trial.
-
Monoclonal CCR5 antibody for treatment of people with HIV infection.Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008439. doi: 10.1002/14651858.CD008439.pub2. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2014 Jul 26;(7):CD008439. doi: 10.1002/14651858.CD008439.pub3. PMID: 21154397 Updated. Review.
-
Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.Antimicrob Agents Chemother. 2019 May 24;63(6):e00110-19. doi: 10.1128/AAC.00110-19. Print 2019 Jun. Antimicrob Agents Chemother. 2019. PMID: 30885900 Free PMC article. Review.
Cited by
-
Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection.Drugs. 2020 Feb;80(2):189-196. doi: 10.1007/s40265-020-01258-3. Drugs. 2020. PMID: 31970712 Review.
-
HIV-1 antiretroviral drug therapy.Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161. doi: 10.1101/cshperspect.a007161. Cold Spring Harb Perspect Med. 2012. PMID: 22474613 Free PMC article. Review.
-
Macrophage Tropism in Pathogenic HIV-1 and SIV Infections.Viruses. 2020 Sep 25;12(10):1077. doi: 10.3390/v12101077. Viruses. 2020. PMID: 32992787 Free PMC article. Review.
-
Candidate antibody-based therapeutics against HIV-1.BioDrugs. 2012 Jun 1;26(3):143-62. doi: 10.2165/11631400-000000000-00000. BioDrugs. 2012. PMID: 22462520 Free PMC article. Review.
-
In vivo binding and retention of CD4-specific DARPin 57.2 in macaques.PLoS One. 2010 Aug 27;5(8):e12455. doi: 10.1371/journal.pone.0012455. PLoS One. 2010. PMID: 20805996 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
